Drugs / Ultrase® MT12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00880100 | Apr → Nov 2009 | cystic fibrosis, exocrine pancreatic insufficiency | Forest Laboratories | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultrase MT12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00880100 ↗ |
| Route | Oral | “Ultrase® MT12 capsules will be given orally daily” NCT00880100 ↗ |